2025-10-24 - Analysis Report
Okay, here's an analysis of Natera Inc. (NTRA) based on the data provided, formatted as requested:

## NTRA (Natera Inc.) Analysis

**Company Overview:** Natera Inc. is a diagnostics company focused on cell-free DNA testing for reproductive health, oncology, and organ health.

### 1. Performance vs. S&P 500 (VOO)

*   **NTRA Cumulative Return:** 93.09%
*   **VOO Cumulative Return:** 99.36%
*   **Absolute Deviation:** -9.5
*   **Relative Deviation:** 30.0

**Analysis:** NTRA has underperformed the S&P 500 in terms of cumulative return. The relative deviation of 30.0 indicates that the current deviation is in the lower end of its historical range compared to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha  | Beta  | Cap(B) |
|------------|---------|-------|--------|-------|--------|
| 2015-2017  | -10.0%  | 69.9% | -34.0% | -0.1  | 1.3    |
| 2016-2018  | 22.0%   | 80.0% | 7.0%   | 0.1   | 2.0    |
| 2017-2019  | 50.0%   | 80.0% | 28.0%  | 1.0   | 4.8    |
| 2018-2020  | 186.0%  | 80.5% | 162.0% | 1.1   | 14.2   |
| 2019-2021  | 96.0%   | 80.5% | 49.0%  | 1.6   | 13.4   |
| 2020-2022  | -77.0%  | 80.5% | -76.0% | 0.1   | 5.8    |
| 2021-2023  | -193.0% | 76.7% | -195.0%| -1.1  | 9.0    |
| 2022-2024  | 8.0%    | 76.7% | -13.0% | -1.1  | 22.7   |
| 2023-2025  | 120.0%  | 76.7% | 57.0%  | 0.1   | 26.8   |

**Analysis:**
* CAGR: The Compound Annual Growth Rate (CAGR) has been highly volatile, ranging from -193% to 186% over different 3-year periods. The most recent period (2023-2025) shows a strong positive CAGR of 120%.
* MDD: The Maximum Drawdown (MDD) is consistently high, indicating significant risk and price volatility.
* Alpha: Alpha measures the performance of the investment compared to a benchmark. Positive alpha indicates outperformance, while negative alpha indicates underperformance.
* Beta: Beta measures the volatility of the investment relative to the market. A beta of 1 suggests the investment moves with the market, while a beta greater than 1 suggests it is more volatile than the market.
* Market Cap: Market Cap fluctuates over time

### 2. Recent Stock Price Movement

*   **Current Price:** 186.88
*   **Last Market:** Price: 195.0, Previous Close: 188.02, Change: 3.71
*   **5-day Moving Average:** 183.43
*   **20-day Moving Average:** 170.79
*   **60-day Moving Average:** 164.32

**Analysis:** The stock price is above all three moving averages, indicating an upward trend. The recent price surge reflected in Last-market price with change is a significantly positive movement.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 78.99 (Overbought)
*   **PPO:** 1.0852
*   **Hybrid Signal:** Buy 100%
*   **Delta_Previous_Relative_Divergence (20-day):** 3.6 (Positive - Short-term increase)
*   **Expected Return (%):** -108.8%

**Analysis:** The MRI suggests a generally favorable investment environment. However, the high RSI indicates the stock might be overbought and could be due for a correction. The positive change in relative divergence confirms the recent upward momentum. Despite this, the negative expected return suggests potential underperformance relative to the S&P 500 over the long term.

### 4. Recent News & Significant Events

*   **Positive News:**
    *   Successful IMvigor011 Trial: Improved overall survival for bladder cancer patients.
    *   Fast Company's Next Big Things in Tech List: Recognition for innovation.
    *   Bull Case Following Breakthrough Study Results: Positive outlook for Signatera platform.
    *   Why Are Natera (NTRA) Shares Soaring Today

**Analysis:** Recent news seems to be overwhelmingly positive, focusing on clinical trial success, innovation recognition, and positive analyses. This news likely contributed to the recent stock price surge.

### 4-2. Analyst Opinions

*   **Consensus:** Buy
*   **Mean Rating:** 1.53 (~Buy)
*   **Target Price:** 194.47 / 235.00 / 37.00
*   **Opinions:** 19

**Analysis:** Analyst consensus is strongly positive, with a "Buy" rating and an average target price above the current price, suggesting potential upside. However, the wide range in target prices (37.00 to 235.00) indicates considerable uncertainty among analysts.

### 5. Recent Earnings Analysis

| 날짜       | EPS    | 매출      |
|------------|--------|-----------|
| 2025-08-08 | -0.74  | 0.55 B$   |
| 2025-05-09 | -0.5   | 0.50 B$   |
| 2024-11-12 | -0.26  | 0.44 B$   |
| 2024-08-09 | -0.3   | 0.41 B$   |
| 2025-08-08 | -0.3   | 0.41 B$   |

**Analysis:** While revenue is generally increasing, the company is still reporting negative EPS (Earnings Per Share), indicating a lack of profitability.

### 6. Financial Information

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.55B  | 63.41%        |
| 2025-03-31 | $0.50B  | 63.12%        |
| 2024-12-31 | $0.48B  | 62.94%        |
| 2024-09-30 | $0.44B  | 61.79%        |
| 2024-06-30 | $0.41B  | 58.83%        |

| Quarter    | Equity  | ROE     |
|------------|---------|---------|
| 2025-06-30 | $1.25B  | -8.10%  |
| 2025-03-31 | $1.24B  | -5.40%  |
| 2024-12-31 | $1.20B  | -4.50%  |
| 2024-09-30 | $0.88B  | -3.60%  |
| 2024-06-30 | $0.84B  | -4.48%  |

**Analysis:** Revenue and profit margins are consistently increasing. Equity is also increasing, but ROE (Return on Equity) remains negative, reflecting the company's ongoing unprofitability.

### 7. Overall Analysis

Natera Inc. (NTRA) presents a mixed picture.

**Positives:**

*   **Strong Revenue Growth & High Profit Margins:** The company is demonstrating healthy revenue growth and maintaining high profit margins.
*   **Positive Analyst Sentiment:** Analysts have a generally positive outlook on the stock with "Buy" ratings.
*   **Recent Positive News:** Breakthrough study results for Signatera Platform and other news
*   **Technological Innovation:** Company has been named in Fast Company’s Next Big Things in Tech List

**Negatives:**

*   **Unprofitability:** The company is still not profitable, with negative EPS and ROE.
*   **High Volatility:** High MDD values indicate significant price volatility.
*   **Underperformance vs. S&P 500:** NTRA has underperformed the S&P 500 over the analyzed period.
*   **Negative Expected Return:** Long-term projections suggest potential underperformance relative to the S&P 500.

**Conclusion:**

NTRA appears to be a high-growth, high-risk investment. The recent positive momentum, driven by clinical trial successes and analyst upgrades, could continue in the short term. However, investors should be aware of the company's ongoing unprofitability, high volatility, and negative long-term expected return. The RSI suggests the stock may be overbought, so a pullback is possible. The stock is suitable for investors with a high-risk tolerance and a long-term investment horizon, who are willing to bet on the company's future profitability and continued innovation.
